Dapoxetine

Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that is unusual within its class for being designed and used on demand rather than taken daily. Chemically it is a short-acting SSRI, rapidly absorbed and just as rapidly eliminated, which is precisely the pharmacokinetic profile wanted for a medication taken a few hours before an anticipated event rather than continuously ^[1]. It was originally investigated as an antidepressant but was repurposed and developed specifically for the treatment of premature ejaculation, the most common male sexual complaint.

Marketed under the brand name Priligy, dapoxetine became the first drug developed and licensed expressly for premature ejaculation. Its efficacy and safety were established in a large Phase III program: a prospectively defined integrated analysis of two placebo-controlled trials in the United States, followed by a broader integrated analysis pooling five trials that enrolled more than 6,000 men across dozens of countries ^[1][2]. On the strength of these data it has been approved in many European and Asian countries, although it is not approved by the United States Food and Drug Administration, so its regulatory status varies by region.

As a prescription medicine dapoxetine is taken orally as a tablet, in the on-demand fashion its short half-life is built for, and it is distinct from the older, off-label use of daily SSRIs such as paroxetine or sertraline for the same condition. It is generally well tolerated, with the most common side effects being nausea, dizziness, and headache; importantly, validated assessments in its trials found none of the mood changes, akathisia, suicidality, or withdrawal syndrome sometimes associated with long-term SSRI use, consistent with its brief, intermittent dosing ^[1][2].

Dapoxetine is a short-acting SSRI and shares the class's effects: nausea, dizziness, headache, insomnia, and diarrhea, plus a notable risk of orthostatic hypotension and syncope that has driven cautious dosing and monitoring. Combining it with MAOIs, other serotonergic drugs, or potent CYP inhibitors can precipitate serotonin syndrome, and it is generally contraindicated in significant cardiac disease. As with all SSRIs, mood changes and rare suicidal ideation warrant attention, and it should not be combined with recreational serotonergic substances.

Dapoxetine was originally synthesized in the late 1980s by Eli Lilly and investigated as an antidepressant, but its rapid absorption and short elimination half-life made it poorly suited to daily mood therapy. Those same pharmacokinetics proved ideal for on-demand use, and rights to the molecule were later taken up by ALZA and Johnson & Johnson, which developed it specifically for premature ejaculation. It became the first pharmaceutical developed and approved for that indication, gaining its earliest European approval around 2009 under the trade name Priligy and subsequently spreading across much of Europe and Asia. Its clinical development was supported by large Phase III trials that established its efficacy and as-needed dosing profile.

Dapoxetine is widely regarded as the best-evidenced pharmaceutical option for premature ejaculation, a distinction earned through large, rigorously conducted Phase III trials involving thousands of men. Its appeal is practical and well documented: it works from the very first dose, roughly triples the stopwatch-measured time to ejaculation, and clears the body quickly, which suits its intended as-needed use and avoids the withdrawal and mood effects of continuous SSRIs. Patient-reported gains in control and satisfaction reinforce its standing. Honest discussion notes that, because the mechanism is serotonergic, its side effects mirror a mild, short-lived SSRI effect, with nausea, dizziness, and headache the most common complaints.